- This is what the European Commission says in an interim report Teva Pharmaceutical Industries Ltd TEWA Violating European Union (EU) antitrust rules over practices that delay competition from multiple sclerosis drug Copaxone.
- “Effective protection of intellectual property is the key to this scientific advance. We are concerned that Teva may have abused the patent system to protect itself from competitors reported citing the Commission’s head of competition policy, Margrethe Vestager.
- See also: Teva will begin resolving opioid lawsuits nationwide next year.
- Between October 2019 and March 2021, the Commission conducted unannounced inspections at the premises of several Teva subsidiaries over their Copaxone-related practices.
- Suppose the preliminary views of the European Commission are confirmed. In this case, Teva’s behavior violates Article 102 of the Treaty on the Functioning of the European Union, which prohibits abuse of a dominant position.
- Price promotion: TEVA shares traded 0.59% lower at $8.41 in premarket trading on Monday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Read full story here https://www.benzinga.com/news/large-cap/22/10/29199274/teva-under-suspicion-on-practices-to-stave-off-copaxone-competition
